Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Indhold leveret af Proactive Investors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Proactive Investors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
atai life sciences reveals positive clinical trial results and discusses FDA ruling on MDMA
MP3•Episode hjem
Manage episode 434163738 series 2891889
Indhold leveret af Proactive Investors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Proactive Investors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
atai Life Sciences co-founder and co-CEO Dr Srinivas Rao takes Proactive's Stephen Gunnion through the positive results from the Phase 1b trial for VLS-01, emphasizing its excellent tolerability and potential as a best-in-class treatment option. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. VLS-01 is being developed for treatment-resistant depression, a condition that impacts the lives of an estimated 100 million people globally. Srinivas emphasizes the potential of VLS-01 as a best-in-class treatment option, with excellent tolerability, patient-friendly administration and a short 2-hour in-clinic treatment time. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. Rao noted that the next steps include advancing the 120mg dose into a robust Phase 2 trial for treatment-resistant depression, with results expected by the end of next year. He also addressed recent FDA decisions regarding MDMA and how atai's approach in trial design avoids similar pitfalls. Beyond VLS-01, Rao highlighted that the company is progressing its clinical development plans for EMP-01, which is oral R-MDMA, with a Phase 2 trial for social anxiety disorder set to initiate by the end of the year. Don't forget to like this video, subscribe to our channel, and turn on notifications to stay updated with our latest content. #AtaiLifeSciences #ClinicalTrials #VLS01 #MentalHealth #PharmaceuticalResearch #DepressionTreatment #Phase2Trial #FDA #Biotech #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episoder
MP3•Episode hjem
Manage episode 434163738 series 2891889
Indhold leveret af Proactive Investors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Proactive Investors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
atai Life Sciences co-founder and co-CEO Dr Srinivas Rao takes Proactive's Stephen Gunnion through the positive results from the Phase 1b trial for VLS-01, emphasizing its excellent tolerability and potential as a best-in-class treatment option. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. VLS-01 is being developed for treatment-resistant depression, a condition that impacts the lives of an estimated 100 million people globally. Srinivas emphasizes the potential of VLS-01 as a best-in-class treatment option, with excellent tolerability, patient-friendly administration and a short 2-hour in-clinic treatment time. The trial revealed that the formulation exceeded expectations, particularly in terms of pharmacokinetics, with results comparable to intravenous administration. Rao noted that the next steps include advancing the 120mg dose into a robust Phase 2 trial for treatment-resistant depression, with results expected by the end of next year. He also addressed recent FDA decisions regarding MDMA and how atai's approach in trial design avoids similar pitfalls. Beyond VLS-01, Rao highlighted that the company is progressing its clinical development plans for EMP-01, which is oral R-MDMA, with a Phase 2 trial for social anxiety disorder set to initiate by the end of the year. Don't forget to like this video, subscribe to our channel, and turn on notifications to stay updated with our latest content. #AtaiLifeSciences #ClinicalTrials #VLS01 #MentalHealth #PharmaceuticalResearch #DepressionTreatment #Phase2Trial #FDA #Biotech #DrugDevelopment #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episoder
All episodes
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.